Professor, Urology, Mayo Medical School
Urology
Dr. Eugene D. Kwon, MD
|
|
Give Review
Eugene Kwon works in the field of Urology. He researched medicine at Rush Medical College. He received awards:"Honorable Discharge", "Award", "Pfizer Scholar", "Ruben H. Flocks Distinguished Teaching Award", "Outstanding Performance Urology Inservice Award", "Teacher of the Year, Resident", "Genitourinary Reconstructive Surgeon's Research Award", "Outstanding Research Award", "Traveling Fellow Research Award", "Teacher of the Year, Finalist, Resident" and "Undergraduate Research Award Grant Recipient". Eugene Kwon is a published MD as well. He has 74 publications published. The latest was: Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. He is registered with Medicare.
Publications
- Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation.
- Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma.
- Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
- Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
- Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
- Operational Characteristics Of 11 C-Choline PET/CT For Prostate Cancer Patients With Biochemical Recurrence Following Initial Treatment.
- B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.
- Soluble B7-H1: Differences in production between dendritic cells and T cells.
- B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival.
- Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent Prostate cancer.
- Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
- Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome.
- B7-H1 expression in vestibular schwannomas.
- Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than pr...
- T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
- TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.
- Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.
- Expression of immunosuppresive B7-H3 ligand by hormone-treated Prostate cancer tumors and metastases.
- Long-term outcomes of radical Prostatectomy with multimodal adjuvant therapy in men with a preoperative serum Prostate-specific antigen level > or =50 ng/mL.
- Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation.
- Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
- Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal ...
- Serum-soluble B7x is Elevated in renal cell carcinoma patients and is associated with advanced stage.
- Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.
- T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
- Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas.
- Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
- B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.
- External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.
- Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.
- Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
- Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.
- Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
- B7-H3 ligand expression by Prostate cancer: a novel marker of prognosis and potential target for therapy.
- Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
- Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion.
- PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
- Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
- PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
- Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
- Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
- Implications of B7-H1 expression in clear cell carcinoma of the Kidney for prognostication and therapy.
- Significance of B7-H1 overexpression in Kidney cancer.
- The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
- Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.
- Second primary malignancies associated with renal cell carcinoma histological subtypes.
- Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of Prostate cancer.
- Outcomes of Gleason score 10 Prostate carcinoma treated by radical Prostatectomy.
- Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
- B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with Cancer progression and survival.
- High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
- Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
- Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
- The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
- Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
- Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
- Prostate cancer immunology: biology, therapeutics, and challenges.
- B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
- A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
- Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
- Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
- Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
- Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
- Cancer Specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
- Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
- pT2 classification for renal cell carcinoma. Can its accuracy be improved?
- Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
- Augmentation of T cell levels and responses induced by androgen deprivation.
- Immunotherapy for urological malignancies.
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Schools
Rush Med Coll Of Rush Univ
Conditions Treated
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Elevated PSA (Prostate Specific Antigen)
- Enlarged Prostate (BPH)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Honorable Discharge
- Award
- Pfizer Scholar
- Ruben H. Flocks Distinguished Teaching Award
- Outstanding Performance Urology Inservice Award
- Teacher of the Year, Resident
- Genitourinary Reconstructive Surgeon's Research Award
- Outstanding Research Award
- Traveling Fellow Research Award
- Teacher of the Year, Finalist, Resident
- Undergraduate Research Award Grant Recipient
Education
-
University of Iowa Hospitals and Clinics -
Rush Medical College
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1699754168 | |
| NPPES Provider LastName | KWON | |
| NPPES Provider FirstName | EUGENE | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Urology | |
| Total Claim Count | 876.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 2.51 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699754168 |
| Last Name Of The Provider | KWON |
| First Name Of The Provider | EUGENE |
| View All |
Similar Doctors
|
|
Dr. Stephen A. Boorjian, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Reza S. Malek, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael L. Blute, MD |
|
|
Dr. Mitra R. De Cogain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noel R. Peterson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Candace F. Granberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew N. McCall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne B. Stewart, MD
This Doctor is OpenDoctor Recommended.
|